from semaglutide to tirzepatide vs. Semaglutide: What You Should Know Tirzepatide Outperforms Semaglutide in Blood
Description
The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer
After discontinuation, there was a pronounced rebound in weight (MD=4.13 kg, 95% CI: 1.60 to 6.65), BMI (MD=0.84 kg/m2, 95% CI: 0.37 to 1.32), WC (MD=3.64 cm, 95% CI: 2.27 to 5.01), and HbA1c (SMD=0.69, 95% CI: 0.50 to 0.89)
Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease
Telehealth and in-office consultations
Researchers collected data from adults aged 40 years and older with type 2 diabetes from Canada, Denmark, Norway, South Korea, Sweden and Taiwan who filled a prescription for a GLP-1 receptor agonist (n =
